Amyloid Precursor Protein (APP, Amyloid beta (A4) Precursor Protein) (Control Peptide)
465.63 $
For reserch purpose only
Shipping cost plus VAT not included , delivery in 7-14 business days
Catalog No
USB-A2275-69K
Supplier
US Biologicals
Size
100 µg
Product Overview
Product Properties
Target Gene
Product Overview
| Description | Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by progressive loss of memory and cognition in the elderly. One of the most important and initial step involves proteolytic cleavage of amyloid precursor protein (APP, chromosome 21) releasing short 40, 42 & 43 aa peptides (beta amyloid1-40,1-42, and 1-43; approx. 4.5kD). Polymerization of b-amyloid (Ab) and subsequent neuronal deposit (amyloid) leads to the degeneration of neurons involved in memory and cognition. Ab deposits have also been found to contain 2 additional proteins termed a-synuclein and b-synuclein. APP gene has 19 exons (1). At least 8 different types of APP (APP695, APP751, and APP770 are the major ones) are produced as a result of alternative splicing of exons 7, 8, and 15. Exons 7 codes for a 57-aa domain that is analogous to Kunitz protease inhibitors (KPI). Exon 8 codes for a 19-aa residue domain with homology to the MRC OX-2 antigen found on the membrane of neurons, while exon 15 codes for an 18-aa domain, 16 aa aa proximal to the Ab region. APP695 lacks exons 7 and 8, whereas APP770 and APP751 represents the full length and the exon 8 lacking isoform. Beta amyloid A4 protein represents 597-638 aa of APP695 (28 aa from the extracellular domain and 14-15 aa from the extracellular domain). APP695 is predominantly expressed in the brain while APP751 and APP770 are also found in other tissues. |
| Source Antigen | Human synthetic peptide |
| Reactivity | |
| Cross Reactivity | |
| Applications | |
| Molecular Weight |
Product Properties
| Storage | -20°C |
| Grade | Highly Purified |
| Purity | |
| Form | |
| Reactivity Life | 12 months |
| Note | For reserch purpose only |
Target Gene
NA
